Merck Serono, Kadimastem collaborate on cell-based drug screening

Merck Serono and Israel's Kadimastem signed a memorandum of understanding aimed at advancing their stem cell-based drug screening collaboration initiated in 2012, the companies said on Monday. Kadimastem has developed technologies to differentiate stem cells into oligodendrocytes, which are brain cells that produce myelin, the insulation for the neural wiring. Kadimastem and Merck Serono have been leveraging cell-based drug screening technology to discover compounds that stimulate differentiation and myelination. "Kadimastem offers us a unique, human-cell based, screening model allowing us to better identify promising compounds at an earlier stage in development," Annalisa Jenkins, head of global development and medical for Merck Serono, said.



via Health News Headlines - Yahoo! News http://news.yahoo.com/merck-serono-kadimastem-collaborate-cell-based-drug-screening-092113929--finance.html